B8R 20-27 Peptide TSYKFESV • H-2Kb

Product number: EP08851_1

€ 105.00 *

Prices excl. VAT plus shipping costs

Available, delivery time: 1-3 days

sterile and endotoxin free

Delivery Format: The product is supplied freeze dried.

Purity: 95% HPLC-MS

Caution: For research use only. Not for use in humans.

Amount in mg

Add to Cart

Description

TechData

Documents

Description

The linear peptide B8R 20-27, with the amino acid sequence TSYKFESV (epitope ID 66504), is a well-established H2-Kb-restricted epitope conserved among various Vaccinia virus strains. [1] It is part of the:

Soluble interferon gamma receptor OPG193 (UniProt:P24770) from Vaccinia virus
IFN-gamma receptor (UniProt:Q66793) from Ectromelia mousepox virus
IFN-gamma receptor-like protein (UniProt:G0XTP5) from Cowpox virus

The Vaccinia virus was the live vaccine used to eradicate smallpox. It belongs to the orthopoxvirus family and provides protection against a range of orthopoxviruses. Currently, the most concerning of these is the monkeypox virus, but human cowpox infections are also being reported regularly in Europe. [1]

The B8R 20-27 peptide, TSYKFESV, is also contained in recombinant and non-recombinant Modified Vaccinia virus Ankara (MVA). [1] The Modified Vaccinia virus Ankara has greatly reduced virulence and can no longer replicate in most mammalian cells. [2] It is often used as a vaccine vector, due to its cost-effectiveness, safety, and high immunogenicity. Recombinant MVA vaccines can generate robust humoral and cellular immune responses against various pathogens.

In vaccine development, the B8R 20-27 peptide is used as a positive control to demonstrate that a lack of response is not due to immunization failure. The vaccinia virus B8R gene encodes a homolog of the secreted IFN-γ receptor. By binding to IFN-γ, B8R neutralizes its antiviral activity and is therefore involved in virus evasion of host interferon responses. [1,3]

You can read a current application example in our blog post "Vaccines against Chlamydia trachomatis: Immunogenicity analysis via peptide pool" or view the original publication [4] via the link under the References tab.

TechData

Sequence:	TSYKFESV
Delivery:	1-3 days
C-Terminus:	OH
N-Terminus:	H
Amount:	1 mg
Counterion:	TFA
Protein:	Vaccinia virus WR epitope B8R
IEDB Id:	66504
Species:	Vaccinia virus (VACV)
Allele:	H-2Kb
Application:	Flow Cytometry
Indication:	Infectious disease, Control
Purity:	95% HPLC-MS

Documents

Storage and handling of peptides

Probing of membranes with HRP

More Control Peptides and Peptide Pools

Tip

Packaging of the peptides with a world map in the background

Actin Peptide Pool, human

The HUMAN (Actin) Peptide Pool consists of 92 overlapping peptides derived from a peptide scan through Actin, alpha skeletal muscle (UniProt ID: P68133) of Homo sapiens. The peptides are 15mers that overlap by 11 amino acids. One unit of HUMAN (Actin) Peptide Pool allows the stimulation of 2,5 x 108 cells. Actin is a ubiquitously expressed protein and therefore an excellent negative control for T cell assays. Relevant controls are critical for measuring antigen-specific responses as they allow accurate interpretation of test results. The HUMAN (Actin) Peptide Pool can rule out non-specific binding of peptides to the tested T cells, while a negative control with medium detects general background signals. Examples of publications where actin was used as a negative control: Baker FL, et al.: Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2. Brain Behav Immun Health. 2023 Mar;28:100600. doi: 10.1016/j.bbih.2023.100600. Sweeney, E et al.: Photothermal Prussian blue nanoparticles generate potent multi‐targeted tumor‐specific T cells as an adoptive cell therapy. Bioeng Transl Med. 2023;e10639. doi.org/10.1002/btm2.10639. Roy, P et al.: Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B. Circ Res. 2022 Jul 22;131(3):258-276. doi: 10.1161/CIRCRESAHA.122.321116. Lasagna, Angioletta et al. “The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.”Human vaccines & immunotherapeutics vol. 19,3 (2023): 2288282. doi:10.1080/21645515.2023.2288282

€237.50*

CEF (classic) Peptide Pool (>95% HPLC)

The CEF peptide pool is a lyophilized mixture of 23 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells. The peptides of this product are supplied as trifluoracetate salts. One unit allows the stimulation of 2,5 x 108 cells.

€126.30*

CEF control Peptide Pool (>95% HPLC, advanced)

The CEF peptide pool is a lyophilized mixture of 32 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses, and can be used as a positive control to stimulate T cells. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells. One unit allows the stimulation of 2,5 x 108 cells.These are sequence, source and corresponding MHC class I molecule of each peptide: Sequence Source MHC class I molecule H-VSDGGPNLY-OH Influenza A PB1 HLA-A1 H-CTELKLSDY-OH Influenza A NP HLA-A1 H-GILGFVFTL-OH Influenza A M1 HLA-A2 H-FMYSDFHFI-OH Influenza A PA HLA-A2 H-CLGGLLTMV-OH EBV LMP2A HLA-A2 H-GLCTLVAML-OH EBV BMLF1 HLA-A2 H-NLVPMVATV-OH HCMV pp65 HLA-A2 H-KTGGPIYKR-OH Influenza A NP HLA-A68 H-RVLSFIKGTK-OH Influenza A NP HLA-A3 H-ILRGSVAHK-OH Influenza A NP HLA-A3 H-RVRAYTYSK-OH EBV BRLF-1 HLA-A3 H-RLRAEAQVK-OH EBV EBNA-3A HLA-A3 H-SIIPSGPLK-OH Influenza A M1 HLA-A3/A11/A6 H-AVFDRKSDAK-OH EBV EBNA-3B (4) HLA-A11 H-IVTDFSVIK-OH EBV EBNA-3B HLA-A11 H-ATIGTAMYK-OH EBV BRLF-1 HLA-A11 H-DYCNVLNKEF-OH EBV BRLF-1 HLA-A24 H-LPFDKTTVM-OH Influenza A NP HLA-B7 H-RPPIFIRRL-OH EBV EBNA-3A HLA-B7 H-ELRSRYWAI-OH Influenza A NP HLA-B8 H-RAKFKQLL-OH EBV B2LF-1 HLA-B8 H-FLRGRAYGL-OH EBV EBNA 3A HLA-B8 H-QAKWRLQTL-OH EBV EBNA 3 HLA-B8 H-SDEEEAIVAYTL-OH HCMV HLA-B18 H-SRYWAIRTR-OH Influenza A NP HLA-B27 H-ASCMGLIY-OH Influenza A M1 HLA-B27 H-RRIYDLIEL-OH EBV EBNA 3C HLA-B27 H-YPLHEQHGM-OH EBV EBNA 3A HLA-B35 H-IPSINVHHY-OH CMV pp65 HLA-B35 H-EENLLDFVRF-OH EBV HLA-B44 H-EFFWDANDIY-OH HCMV HLA-B44 H-TPRVTGGGAM-OH HCMV HLA-B7 For more information and application examples, read our blog posts: "Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I expression" "Quality control of peptide pools in personalized cancer therapy"

€151.30*

CMV Sub Peptide Pool (>95% HPLC)

This peptide pool consists of 14 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from cytomegalovirus (CMV).

€138.20*

Only 8 available

CT45A1 Peptide Pool, human

Pool of 45 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through cancer/testis antigen family 45 member A1 (Uniprot ID: Q5HYN5) of Homo sapiens (Human) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€206.30*

EBV control Peptide Pool (>95% HPLC)

This peptide pool consists of 26 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Epstein-Barr virus (EBV): SequenceCorresponding Catalog PeptideAllel1CLGGLLTMVEBV LMP-2 426-434 PeptideHLA-A*02:012GLCTLVAMLEBV BMLF-1 280-288 PeptideHLA-A*02:013FLDKGTYTLEBV BALF-4 276-284 PeptideHLA-A*02:014FLYALALLLEBV LMP2 356-364 PeptideHLA-A*02:015YLLEMLWRLEBV LMP-1 125-133 PeptideHLA-A*02:016RVRAYTYSKEBV BRLF-1 148-156 PeptideHLA-A*03:017RLRAEAQVKEBV EBNA-3A 603-611 PeptideHLA-A*03:018ATIGTAMYKEBV BRLF1 134-142 PeptideHLA-A*11:019AVFDRKSDAKEBV EBNA 3B 399-408 PeptideHLA-A*11:0110IVTDFSVIKEBV EBNA3B 416-424 PeptideHLA-A*11:01HLA-A*68:0111SSCSSCPLSKEBV LMP-2 340-349 PeptideHLA-A*11:0112DYCNVLNKEFEBV BRLF1 28-37 PeptideHLA-A*24:0213PYLFWLAAIEBV LMP2 131-139 PeptideHLA-A*24:0214TYGPVFMCLEBV LMP-2 419-427 PeptideHLA-B*24:0215TYGPVFMSLEBV LMP2 419-427 mutant 426S PeptideHLA-A*24:0216RPPIFIRRLEBV EBNA-3A 379-387 PeptideHLA-B*07:0217QPRAPIRPIEBV EBNA-3C 881-889 PeptideHLA-B*07:0218FLRGRAYGLEBV EBNA-3A 325-333 PeptideHLA-B*08:0119RAKFKQLLEBV BZLF-1 190-197 PeptideHLA-B*08:0120RRIYDLIELEBV EBNA 3C 258-266 PeptideHLA-B*27:02HLA-B*27:05HLA-B*27:0421YPLHEQHGMEBV EBNA-3A 458-466 PeptideHLA-B*35:0122EPLPQGQLTAYEBV BZLF-1 54-64 PeptideHLA-B*35:0123HPVGEADYFEYEBV EBNA-1 407-417 PeptideHLA-B*35:0124IEDPPFNSLEBV LMP2 200-208 PeptideHLA-B*40:0125EENLLDFVRFEBV EBNA3C 281-290 PeptideHLA-B*44:0526QAKWRLQTLEBV EBNA3A 158-166 PeptideHLA-B*08:01 One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

Tip

HBV control Peptide Pool (>95% HPLC)

This peptide pool consists of 9 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Hepatitis B virus (HBV): SequenceCorresponding Catalog PeptideAllel1FLLSLGIHLHBV polymerase 575-583 PeptideHLA-A*02:012FLLTRILTIHBV envelope 183-191 PeptideHLA-A*02:013FLPSDFFPSIHBV core 18-27 (subtype ADR4) PeptideHLA-A*02:014FLPSDFFPSVHBV core 18-27 PeptideHLA-A*02:015GLSPTVWLSVHBV envelope 348-357 PeptideHLA-A*02:016WLSLLVPFVHBV envelope 335-343 PeptideHLA-A*02:017YVNVNMGLKHBV core antigen 88-96 PeptideHLA-A*11:018EYLVSFGVWHBV core 117-125 PeptideHLA-A*24:029KYTSFPWLLHBV polymerase 756-764 PeptideHLA-A*24:02

€215.00*

HCMVA (IE1) Peptide Pool

Peptide pool of 120 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through 55 kDa immediate-early protein 1 (IE-1) (UniProt ID: P13202) of Human cytomegalovirus (HHV-5) frequently used as positive control One unit allows the stimulation of 2,5 x 108 cells.

€301.30*

HCMVA (IE2) Peptide Pool

Peptide pool of 143 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through 45 kDa immediate-early protein 2 (IE-2) (UniProt ID: P19893) of Human cytomegalovirus (HHV-5) frequently used as positive control One unit allows the stimulation of 2,5 x 108 cells.

€301.30*

Tip

HCV Sub Peptide Pool (>95% HPLC)

This peptide pool consists of 21 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Hepatitis C virus (HCV): SequenceCorresponding Catalog PeptideAllel1ATDALMTGFHCV NS3 1436-1444 PeptideHLA-A*01:012ATDALMTGYHCV NS3 1436-1444 mutant 1444Y PeptideHLA-A*01:013ALYDVVTKLHCV NS5B 2594-2602 PeptideHLA-A*02:014CINGVCWTVHCV NS3 1073-1081 PeptideHLA-A*02:015CVNGVCWTVHCV NS3 1073-1081 mutant 1074V PeptideHLA-A*02:016DLMGYIPAVHCV core 132-140 PeptideHLA-A*02:017DLMGYIPLVHCV core 132-140 mutant 139L PeptideHLA-A*02:018GLQDCTMLVHCV NS5B 2727-2735 PeptideHLA-A*02:019KLSGLGINAVHCV (gt. 1b, isol. BK) NS3 1406-1415 PeptideHLA-A*02:0110KLVALGINAVHCV NS3 1406-1415 PeptideHLA-A*02:0111LLFNILGGWVHCV NS4b 1807-1816 PeptideHLA-A*02:0112VLSDFKTWLHCV NS5a 1992-2200 PeptideHLA-A*02:0113YLLPRRGPRLHCV core 35-44 PeptideHLA-A*02:0114RVCEKMALYHCV NS5B 2588-2596 PeptideHLA-A*03:0115AYSQQTRGLHCV NS3 1031-1039 PeptideHLA-A*24:0216DPRRRSRNLHCV core 111-119 PeptideHLA-B*07:0217GPRLGVRATHCV core 41-49 PeptideHLA-B*07:0218HSKKKCDELHCV NS3 1395-1403 PeptideHLA-B*08:0119CPNSSIVYHCV E1 207-214 PeptideHLA-B*35:0120HPNIEEVALHCV NS3 1359-1367 PeptideHLA-B*35:0121REISVPAEILHCV NS5a 2266-2275 PeptideHLA-B*40:01

€138.20*

HIV control Peptide Pool (95% HPLC)

The peptides of this product are supplied as trifluoracetate salts. This pool consists of 22 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from human immunodeficiency virus (HIV): SequenceCorresponding Catalog PeptideAllel1GLADQLIHLHIV-1 Vif 101-109 PeptideHLA-A*02:012ILKEPVHGVHIV-1 RT 476-484 PeptideHLA-A*02:013KLTPLCVTLHIV-1 env gp120 90-98 PeptideHLA-A*02:014LTFGWCFKLHIV-1 Nef 137-145 PeptideHLA-A*02:015SLYNTVATLHIV-1 p17 Gag 77-85 PeptideHLA-A*02:016TLNAWVKVVHIV-1 gag p24 19-27 PeptideHLA-A*02:017QVPLRPMTYKHIV-1 nef 73-82 PeptideHLA-A*03:018RLRPGGKKKHIV-1 gag p17 20-28 PeptideHLA-A*03:019RYLKDQQLLHIV Env gp160 585-593 PeptideHLA-A*24:0210RYPLTFGWCYHIV-1 Nef 134-143 PeptideHLA-A*24:0211GPGHKARVLHIV gag p24 223-231 PeptideHLA-B*07:0212IPRRIRQGLHIV-1 env gp120 843-851 PeptideHLA-B*07:0213TPGPGVRYPLHIV-1 nef 128-137 PeptideHLA-B*07:0214FLKEKGGLHIV-1 nef 90-97 PeptideHLA-B*08:0115GEIYKRWIIHIV-1 gag p24 261-269 PeptideHLA-B*08:0116RLRPGGKKKYHIV-1 p17 20-29 PeptideHLA-B*15:0117GRAFVTIGKHIV Env 314-322 PeptideHLA-B*27:0518KRWIILGLNKHIV p24-Gag 263-272 PeptideHLA-B*27:0519KRWIIMGLNKHIV-1 Gag p24 263-272 PeptideHLA-B*27:0520NPDIVIYQYHIV-1 RT 330-338 PeptideHLA-B*35:0121VPLDEDFRKYHIV-1 RT 273-282 PeptideHLA-B*35:0122KEKGGLEGLHIV-1 Nef 92-100 PeptideHLA-B*40:01 One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

Tip

Influenza control Peptide Pool (>95% HPLC)

This pool consists of 17 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from influenza: SequenceCorresponding Catalog PeptideAllel1ILGFVFTLTVInfluenza A M1 59-68 PeptideHLA-A*02:012ILRGSVAHKInfluenza A (PR8) NP 265-274 PeptideHLA-A*03:013KSMREEYRKInfluenza A MP2 70-78 PeptideHLA-A*11:014RMVLASTTAKInfluenza A M1 178-187 PeptideHLA-A*11:015QPEWFRNVLInfluenza A PB1 329-337 PeptideHLA-A*07:026SPIVPSFDMInfluenza A NP 473-481 PeptideHLA-A*07:027CTELKLSDYInfluenza A NP 44-52 PeptideHLA-A*01:018VSDGGPNLYInfluenza A PB1 591-599 PeptideHLA-A*01:019FMYSDFHFIInfluenza Virus PA 46-54 PeptideHLA-A*02:0110GILGFVFTLInfluenza A M1 58-66 PeptideHLA-A*02:0111RVLSFIKGTKInfluenza Virus NP 342-351 PeptideHLA-A*03:01HLA-A*31:01HLA-A*33:0112SIIPSGPLKInfluenza A M1 13-21 PeptideHLA-A*11:01HLA-A*03:01HLA-A*31:01HLA-A*68:0113KTGGPIYKRInfluenza Virus NP 91-99 PeptideHLA-A*68:0114ASCMGLIYInfluenza A M1 125-132 PeptideHLA-B27HLA-B3515SRYWAIRTRInfluenza A NP 383-391 PeptideHLA-A*27:0516LPFDKTTVMInfluenza NP 418-426 PeptideHLA-B*07:0217ELRSRYWAIInfluenza Virus NP 380-388 PeptideHLA-B8 One unit allows the stimulation of 2,5 x 108 cells.

€215.00*

OVA 323-339 Peptide

OVA-Peptid (323-339) is a linear peptidic epitope (epitope ID 28676) with the amino acid sequence ISQAVHAAHAEINEAGR. The peptide is studied as part of Ovalbumin (UniProt:P01012) from chicken. It is a MHC-II binding epitope, stimulating ovalbumin-specific CD4+ T cells. OVA-Peptid (323-339) serves as a negative control, when investigating CD4+ T-cell responses.

From €106.60*

Details

RSV control Peptide Pool (>95% HPLC)

This pool consists of 28 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Respiratory Syncytial Virus (RSV): SequenceCorresponding Catalog PeptideAllel1RELPRFMNYTRSV (A2) fusion glycoprotein F0 precursor 109-118HLA-A*01:012YLEKESIYYRSV MP 229-237 PeptideHLA-A*01:013AITTILAAVRSV Fusion protein 10-18 PeptideHLA-A*02:024ALLSTNKAVRSV Fusion protein 170-178 PeptideHLA-A*02:015ELDKYKNAVRSV Fusion protein 82-90 PeptideHLA-A*02:016FLLGVGSAIRSV Fusion protein 140-148 PeptideHLA-A*02:017FMNYTLNNTRSV Fusion protein 114-122 PeptideHLA-A*02:018HLEGEVNKIRSV Fusion protein 159-167 PeptideHLA-A*02:019KIMTSKTDVRSV Fusion protein 394-402 PeptideHLA-A*02:0110KINQSLAFIRSV Fusion protein 498-506 PeptideHLA-A*02:0111KLMSNNVQIRSV Fusion protein 272-280 PeptideHLA-A*02:0112KMLKEMGEVRSV NP 137-145 PeptideHLA-A*02:0113KVLDLKNYIRSV Fusion protein 191-199 PeptideHLA-A*02:0114LLSLIAVGLRSV Fusion protein 538-546 PeptideHLA-A*02:0115LLSTNKAVVRSV Fusion protein 171-179 PeptideHLA-A*02:0116LMSNNVQIVRSV Fusion protein 273-281 PeptideHLA-A*02:0117QLLSSSKYTRSV NP 16-24 PeptideHLA-A*02:0118SLIAVGLLLRSV Fusion protein 540-548 PeptideHLA-A*02:0119SLSNGVSVLRSV Fusion protein 180-188 PeptideHLA-A*02:0120STNKAVVSLRSV Fusion protein 173-181 PeptideHLA-A*02:0121SVGNTLYYVRSV Fusion protein 451-459 PeptideHLA-A*02:0122YMLTNSELLRSV Fusion protein 250-258 PeptideHLA-A*02:0123RLPADVLKKRSV MP2 151-159 PeptideHLA-A*03:0124NPKASLLSLRSV NP 306-314 PeptideHLA-B*07:0225QVMLRWGVLRSV NP 255-263 PeptideHLA-B*08:0126AELDRTEEYRSV MP2 64-72 PeptideHLA-B4427RARRELPRFRSV Fusion glycoprotein F0 precursor 106-114 PeptideHLA-B5728IAVGLLLYCRSV Fusion glycoprotein F0 precursor 542-550 PeptideHLA-Cw12

€215.00*

Tip

Tetanus Toxin Peptide Pool

Peptide pool of 326 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Tetanus toxin (UniProt ID: P04958) of Clostridium tetani (strain Massachusetts / E88) for T cell assays (e.g. ELISPOT) One unit allows the stimulation of 2,5 x 108 cells.

€475.70*

TSGA10 Peptide Pool, human

Control peptide pool of 172 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through human Testis-specific gene 10 protein (UniProt ID Q9BZW7). One unit allows the stimulation of 2,5 x 108 cells.

€380.70*

Request a Quotation

Your Contact Information

Quotation Sent!

B8R 20-27 Peptide TSYKFESV • H-2Kb

€ 105.00 *

Description

TechData

Documents